3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
NIH
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
4
Other solid neoplasm
3
Tumor-Agnostic
1
Gynecologic
1
Gastrointestinal
1
Breast
1
Conditions
Triple Negative Breast Neoplasms
1
Thymoma
1
Pancreatic Neoplasms
1
Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Gemcitabine
302
Fluorouracil
296
Oxaliplatin
269
Bevacizumab
267
Capecitabine
233
Leucovorin
229
pembrolizumab
215
Irinotecan
185
Cisplatin
142
Cetuximab
142
Nivolumab
131
Paclitaxel
117
130-nm albumin-bound paclitaxel
117
Sorafenib
86
Albumin-Bound Paclitaxel
75
Docetaxel
65
regorafenib
64
atezolizumab
64
IFL protocol
61
Folfox protocol
61
Trastuzumab
54
Panitumumab
47
durvalumab
46
Ramucirumab
43
Injections
43
Sunitinib
41
Drug Therapy
41
Carboplatin
40
trifluridine tipiracil drug combination
38
lenvatinib
38
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
anetumab ravtansine
×
Gastrointestinal
×
Clear all
NCT03102320
2022-06-30
ARCS-Multi
Bayer
Phase 1
Completed
173 enrolled